Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. FDA label
Also known as Hydrochlorothiazide (HCTZ)
Hydrochlorothiazide · 1 trial · 1 indication
10 µl of acetylcholine (ACH) at 3 concentrations (10-7, 10-8, 10-9 M) was injected intra-dermally at 3 sites on the forearms. NaCl was injected at 2 sites on the forearms. Microcirculation was measured using laser doppler velocimetry before and 12 times in the 30 minutes following injection. The mean difference of the 12 post-injection measurements to the pre-injection measurement was calculated. Means for the 3 ACH and the 2 NaCl sites were calculated and compared. Microcirculation was measured in perfusion units which is an arbitrary measure specific to each laser doppler scanner.
| Arm | Type | Description |
|---|---|---|
| Valsartan followed by atenolol + hydrochlorothiazide (HCTZ) | EXPERIMENTAL | After a 2-week washout period, patients were treated with valsartan for 20 weeks followed by one week in which it was tapered off. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. The valsartan dose was then tapered off to 80 mg for one week. Patients took valsartan film coated tablets orally once a day (od) in the morning. After a second 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning. |
| Atenolol + hydrochlorothiazide (HCTZ) followed by valsartan | EXPERIMENTAL | After a 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks followed by one week in which atenolol was tapered off and HCTZ was discontinued. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning. After a second 2-week washout period, patients were treated with valsartan for 20 weeks. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. Patients took valsartan film coated tablets orally once a day (od) in the morning. |
| Name | Type | Description |
|---|---|---|
| Atenolol | DRUG | 100 mg tablets orally once a day (od) in the morning. |
| Hydrochlorothiazide (HCTZ)) | DRUG | 12.5 or 25 mg tablets orally once a day (od) in the morning. |
| Valsartan | DRUG | 80 mg, 160 mg, or 320 mg tablets orally once a day in the morning |
Inclusion Criteria: * Caucasian; male or female outpatients and age between 40-65 years of age, inclusive. * At Visit 2 all patients must have a mean sitting diastolic blood pressure (msSBP) of ≥ 90 mmHg and \< 110 mmHg. Exclusion Criteria: * If a single reading for arterial hypertension in msSBP...
Top 9 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 5 | PHASE3 | Baxdrostat |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Clazakizumab |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | QCZ484, HJB647 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX340 |
Hydrochlorothiazide is used for hypertension, also known as high blood pressure. It belongs to the cardiovascular therapeutic area and is a small molecule drug. In clinical research it has been studied in hypertensive patients, including a Phase 3 trial comparing valsartan versus atenolol and hydrochlorothiazide combination on blood flow.
Hydrochlorothiazide targets SLC12A3. It acts as an inhibitor of this target. SLC12A3 is the sodium chloride cotransporter in the distal convoluted tubule of the kidney, and inhibition of this transporter is the mechanism by which hydrochlorothiazide exerts its pharmacological effect.
Hydrochlorothiazide is developed by Novartis AG, which trades under the ticker NVS. The company is associated with the clinical development program for this small molecule in hypertension.
Hydrochlorothiazide is in Phase 3 development for hypertension. It is an investigational small molecule and is not stated to be FDA approved. The Phase 3 trial in the program has been completed, and there are currently no active trials listed for this asset.
Hydrochlorothiazide has been studied in one completed Phase 3 trial, NCT00396656, titled Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients. The trial enrolled 30 participants, was randomized and controlled, and was conducted in Germany and Switzerland.
Yes, Hydrochlorothiazide is also known as HCTZ. HCTZ is the common abbreviation used for hydrochlorothiazide in clinical and prescribing contexts. Both names refer to the same small molecule drug developed by Novartis AG for hypertension.